Indoco Remedies

Indoco Remedies Gross Margin

The Gross Margin of Indoco Remedies (INDOCO.NS) as of Oct 15, 2026 is 40.72 %. In the previous year, Gross Margin was 39.57 % — a change of 2.90% (higher).

Gross Margin

40.72 %

YoY

2.90%

Last updated:

Gross Margin of Indoco Remedies is 2026 40.72 % . Gross Margin of Indoco Remedies was 2025 39.57 % . It decreases by 2.90% higher compared to the previous year.

For Indoco Remedies, the gross margin of 40.7% is down versus 68.1% a few years ago.

The Indoco Remedies Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
65.65 INR
Jan 1, 2020
68.97 INR
Jan 1, 2021
69.63 INR
Jan 1, 2022
68.11 INR
Jan 1, 2023
67.12 INR
Jan 1, 2024
33.72 INR
Jan 1, 2025
39.57 INR
Jan 1, 2026
40.72 INR
The Indoco Remedies Gross Margin history
YEARGross MarginYoY
40.72 %+2.90%
39.57 %+17.37%
33.72 %-49.77%
67.12 %-1.45%
68.11 %-2.18%
69.63 %+0.95%
68.97 %+5.07%
65.65 %+0.21%
65.51 %+1.08%
64.81 %+2.89%
62.99 %-3.01%
64.94 %+3.29%
62.87 %+10,658.01%
0.58 %+18.22%
0.49 %-11.60%
0.56 %-44.08%
1.00 %0.00%
1.00 %+435.46%
0.19 %-81.32%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd, listed on the National Stock Exchange of India with ticker INDOCO.NS and ISIN INE873D01024, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It employs 6,101 full-time employees and went public via an IPO on January 7, 2005. Indoco Remedies Ltd focuses on the manufacturing and marketing of formulations, including finished dosage forms and active pharmaceutical ingredients (APIs). The company serves multiple therapeutic categories such as diabetology, respiratory care, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicine. Its product portfolio includes brands like Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel. The company caters to both domestic and international markets. Indoco Remedies Ltd has subsidiaries including Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited. The company's website is https://www.indoco.com/. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

Gross Margin of Indoco Remedies is 40.72 % in 2026.

Gross Margin of Indoco Remedies changed from 39.57 % to 40.72 %, representing a 2.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Indoco Remedies

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Indoco Remedies